MDS Virtual Congress 2020 Archives - Page 52 of 149

L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production

S. Martin, V. Jones, J. Taylor, S. Lane, J. Ehlting, A. Helton, P. Walter (Victoria, BC, Canada)
Lack of depotentiation may not be a hallmark of Levodopa-induced dyskinesias

A. Kishore, P. James, S. Krishnan, K. Divya, S. Meunier (Trivandrum, India)
Lack of sensitivity of full-depth upper gastrointestinal specimens as a prodromal biomarker for synucleinopathy in idiopathic REM sleep behavior disorder

C. Shin, S. Park, H. Yang, H. Kim, B. Jeon (Daejeon, Republic of Korea)
Large-Scale Network Changes in the Pathophysiology of Essential Tremor

A. Morris, S. Norris, B. Adeyemo, S. Petersen, A. Snyder, J. Mink, J. Perlmutter (Rochester, NY, USA)
Laryngeal movement disorders as a potential clinical biomarker in multiple system atrophy: Results from the LaPD study

F. Gandor, A. Vogel, I. Claus, S. Ahring, D. Gruber, H.J Heinze, R. Dziewas, G. Ebersbach, T. Warnecke (Beelitz-Heilstätten, Germany)
Late onset Wilson’s disease with hepatic and neurological manifestations

H.J Kim, D.W Kwack, S.H Kim (Seoul, Republic of Korea)
Late-Onset Dopa-Responsive Dystonia: A Case Report

O. Oztop Cakmak, S. Ertan, S. Tekgul, N. Basak (Istanbul, Turkey)
Left-right motor cortex asymmetry in the pathophysiology of essential tremor

C. Ammann, D. Urso, C. Pagge, M. Dileone, J.A Pineda-Pardo, B. Fernández-Rodríguez, M.G Monje, F. Hernández-Fernández, J.U Máñez-Miró, R. Martínez-Fernández, L. Vela, A. Oliviero, J.A Obeso, G. Foffani (Móstoles, Spain)
Leveraging patient-specific models to optimize DBS monopolar review

Y. Pathak, E. Ross, R. Pahwa (Kansas City, KS, USA)
Levodopa and dopamine agonists dosage changes after Opicapone introduction

N. Caballol, A. Planas-Ballvé, A. Ávila (Sant Joan Despí, Spain)
Levodopa Challenge Test for Prediction of Deep Brain Stimulation Efficacy on Motor Functions for Parkinson’s Disease

Z.Y Lin, Y-Y. Zhang, L.B Wang, C-C. Zhang, B.M Sun, D.Y Li (Shanghai, China)
Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients with Parkinson’s Disease

Y.S Shen, W. Liu, M.Y Yu, W.L Liu (Nanjing, China)
Levodopa Dose Equivalency for Opicapone and Safinamide

J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, E. Natera Villalba, A. Beltran Corbellini, A. García Plata, A. Alonso Cánovas (Madrid, Spain)
Levodopa improves tremor symptom by reducing the connectivity between the thalamic subregions and postcentral gyrus in patients with Parkinson’s disease

W.L Liu, Y.S Shen, M.Y Yu, W.L Liu (Nanjing, China)
Levodopa induced changes of tongue body movements during speech production

T. Thies, D. Mücke, R. Dano, M.. Barbe (Cologne, Germany)
Levodopa-induced dyskinesias and substantia nigra dopamine D3 receptor availability in Parkinson’s disease

G. Pagano, S. Molloy, P. Bain, E. Rabiner, K. Chaudhuri, D. Brooks, N. Pavese (Basel, Switzerland)
LFP in motor subtypes of Parkinson’s disease

S. Meka, R. Kandadai, R. Borgohain (Hyderabad, India)
Linguistic Deficits in Patients with Parkinson’s Disease

P. Akkunje, Y. Belur, R. Yadav, A. Rajasekaran, P. Yuvaraj, N. Kamble, S. Shivashankar, P. Pal (Bangalore, Karnataka, India)
LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression

T. Usnich, N. Schell, E.J Vollstedt, V. Skrahina, X. Bogdanovic, N. Koleva-Alazeh, I. Csoti, T. Förster, A. Heuer, N. Brüggemann, P. Bauer, M. Kasten, A. Rolfs, C. Klein (Luebeck, Germany)
Loneliness/Social Isolation as a Risk Factor for Worsened Parkinson Disease Severity

I. Subramanian, L. Mischley, J. Farahnik (Los Angeles, CA, USA)
Long and short survival in Parkinson syndrome: pathology and genetics are key prognostic factors

A. Rajput, C. Robinson, M. Farrer, E. Gustavsson, A. Rajput (Saskatoon, SK, Canada)
Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study

S. Isaacson, W. Poewe, T. Simuni, O. Rosenfeld, R. Case, T. Yardeni, W. Olanow (Boca Raton, FL, USA)
Long-term course and confounding factors of MDS-UPDRS in a longitudinal single-center (DeNoPa) and a multicenter cohort (PPMI)

M. Bartl, M. Dakna, S. Schade, E. Lang, C. Trenkwalder, B. Mollenhauer (Göttingen, Germany)
Long-term course of a case with primary orthostatic tremor

J. Tashiro, H. Ohtsuka, M. Hirotani, Y. Iida, S. Hamada, H. Soma, M. Nonaka, S. Honma, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)
Long-term effect of deep brain stimulation in a monkey model of Parkinson’s disease with L-Dopa–induced dyskinesias

M. Bourque, S. Carrondo-Cottin, M. Parent, L. Cantin, B. Gosselin, M.E Tremblay, T. Di Paolo (Quebec City, QC, Canada)
Long-term effect of non-invasive Vagus Nerve Stimulation in Parkinson’s disease patients

H. Kumar, B. Mondal, S. Choudhury, R. Banerjee, A. Roy, K. Chatterjee, P. Basu, S. Baker, M. Baker (Kolkata, India)
Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

C. Tanner, D. Chernick, A. Formella (San Francisco, CA, USA)
Long-term effects of air pollution on the risk of Parkinson’s disease

Y.S Hwang, S.Y Jo, Y.J Kim, K.W Park, S.H Lee, S.J Chung (Seoul, Republic of Korea)
Long-term quality of life after subthalamic deep brain stimulation depends on non-motor symptoms in Parkinson’s disease

S. Jost, L. Timmermann, A. Rizos, M. Silverdale, J. Evans, P. Loehrer, M. Samuel, J. Petry-Schmelzer, A. Sauerbier, M. Barbe, G. Fink, V. Visser-Vandewalle, K. Ashkan, A. Antonini, P. Martinez-Martin, K. Ray Chaudhuri, H. Dafsari (Cologne, Germany)
Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

M. Sajatovic, A. Wilhelm, S. Finkbeiner, H. Barkay, N. Chaijale, N. Gross, M. Gordon (Cleveland, OH, USA)
Long-term safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: results of a Phase III study

F. Pagan, A. Dekundy, M. Althaus, D. Mitsikostas (Washington, DC, USA)
Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study

R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, L. Marinelli, A. Wilhelm, M. Gordon, J.M Savola, K. Anderson (Tampa, FL, USA)
Longitudinal association between UPDRS and health-related quality of life in people with Parkinson´s disease

A. Reyes, L. Rutten-Jacobs, S. Roumpanis, S. Jauss, P. Coloma (Basel, Switzerland)
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder

J.H Shin, J.Y Lee, Y.K Kim, H.W Nam, S.A Shin, H.J Kim, B. Jeon (Seoul, Republic of Korea)
Longitudinal clinical and imaging characteristics of non-manifest LRRK2 carriers: The PPMI cohort

T. Simuni, A. Siderowf, M. Brumm, C. Caspell, H. Cho, C. Coffey, T. Foroud, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, K. Marek, p. PPMI Investigators (Chicago, IL, USA)
Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington’s disease: the prospective HD-CSF study

F. Rodrigues, L. Byrne, R. Tortelli, E. Johnson, P. Wijeratne, M. Arridge, E. De Vita, D. Alexander, S. Tabrizi, S. Schobel, R. Scahill, A. Heslegrave, H. Zetterberg, E. Wild (London, United Kingdom)
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients and controls: the PPMI study

R. Alcalay, P. Wolf, M.R Chiang, K. Helesicova, X.K Zhang, K. Merchant, S. Hutten, C. Scherzer, C. Caspell-Garcia, C. Blauwendraat, K. Nudelman, T. Foroud, Z. Gan-Or, T. Simuni, L. Chahine, O. Levy, D. Zheng, G. Li, P. Sardi (NEW YORK, NY, USA)
Longitudinal Utility of the Montreal Cognitive Assessment and Mini Mental State Exam in Huntington’s disease (HD)

I. Beltran-Najera, J. Corey-Bloom, C. Snell, A. Smirnova, P. Gilbert (San Diego, CA, USA)
Look Again: The Diagnostic Value of Repeat Dopamine Transporter Imaging

K. Papesh, Z. Mari (Las Vegas, NV, USA)
Loss of CHCHD2 and CHCHD10 disrupts mitochondrial cristae phenocopying patient mutations

D. Narendra, Y. Liu, X. Huang, D. Nguyen, M. Shammas, B. Wu, E. Dombi, D. Springer, J. Poulton, S. Sekine (Bethesda, MD, USA)
Loss of cortical inhibition in Parkinson’s disease

C. Ammann, M. Dileone, C. Pagge, V. Catanzaro, D. Mata-Marín, F. Hernández-Fernández, M.G Monje, A. Sánchez-Ferro, B. Fernández-Rodríguez, C. Gasca-Salas, J.U Máñez-Miró, R. Martínez-Fernández, L. Vela, F. Alonso-Frech, A. Oliviero, J.A Obeso, G. Foffani (Móstoles, Spain)
Loss of Weight Associated with Levodopa / Carbidopa Intestinal Gel

A. Contreras, M. Carrascal, I. Bretón, F. Grandas (Madrid, Spain)
Loss‐of‐function mutations in NR4A2 cause dopa‐responsive dystonia-parkinsonism

T. Wirth, LL. Mariani, G. Bergant, M. Baulac, M.O Habert, N. Drouot, E. Ollivier, A. Hodžic, G.o Rudolf, P. Nitschke, G.a Rudolf, J. Chelly, C. Tranchant, M. Anheim, E. Roze (London, United Kingdom)
Low dose Cabergoline for freezing of gait in advanced Parkinson’s disease – you can have your cake and eat it too!

N. Sharma, A. Kumari, N. Sawal, H. Singh, K. Shukla (Chandigarh, India)
Low Educational Level and Wilson’s disease: A direct path to cognitive decline

J. Lima, F. Rolim, A. Gomes, A. Marinho, V. Mesquita, G. Ferreira, F. Carvalho (Fortaleza, Brazil)
Low Intensity Cycling Combined with Blood Flow Restriction as a Feasible Strategy for Improving Motor Function in Parkinson’s Disease- A Single Case Study

N. Choudhary (Jodhpur, India)
LRRK2 p.G2019S and p.N2081D variants as modifiers of glucocerebrosidase activity

K. Senkevich, E. Yu, L. Krohn, U. Rudakou, J. Ruskey, F. Asayesh, K. Mufti, S. Laurent, D. Spiegelman, S. Fahn, C. Waters, P. Sardi, G. Rouleau, R. Alcalay, Z. Gan-Or (Montreal, QC, Canada)
LSVT LOUD Applied to Adults with Cerebral Palsy: Two Single-Subject Studies

G. Moya-Gale, J. Galgano, C. Ferrone, Y. Chang, G. Tsang, L. Ramig (Brooklyn, NY, USA)